title: Glutathione S-transferase O2 gene rs157077 polymorphism predicts response to transarterial chemoembolization in hepatocellular carcinoma.
abstract: Some genetic alterations of glutathione S-transferase omega 2 (GSTO2) have been reported to increase the risk of many malignancies, including hepatocellular carcinoma (HCC); however, their prognostic capability remained unresolved in HCC patients treated with transarterial chemoembolization (TACE). To fill this gap, we genotyped three well-defined polymorphisms in GSTO2 to assess whether they can predict overall survival among 228 HCC patients under TACE treatment. The median follow-up time and survival time were 22.0 months (range 3.0-60.0) and 19.2 months, respectively. Only one of three polymorphisms examined, rs157077, was significantly associated with overall survival of TACE-treated HCC (P = 0.003), and its mutant allele conferred a higher risk of death than its wild homozygotes (hazard ratio 1.58, 95 % confidence interval 1.17-2.14). Moreover, carriers of this mutant allele had higher tissue GSTO2 expression, reinforcing the prognostic capability of GSTO2 rs157077 for HCC, especially in combination with age and tumor-node-metastasis (TNM) stage. Taken together, we for the first time provided evidence supporting the prognostic role of GSTO2 in the progression of TACE-treated HCC.
authors.affiliation: Department of Hepatobiliary Surgery, The First Affiliated Hospital of Medical College, Xi'an Jiaotong University, Yanta West Road 277, Xi'an, 710061, Shaanxi Province, China.
authors.forename: Zhixin
authors.initials: Z
authors.lastname: Wang
authors.forename: Kai
authors.initials: K
authors.lastname: Qu
authors.forename: Zhichao
authors.initials: Z
authors.lastname: Huang
authors.forename: Xinsen
authors.initials: X
authors.lastname: Xu
authors.forename: Jingyao
authors.initials: J
authors.lastname: Zhang
authors.forename: Li
authors.initials: L
authors.lastname: Zhang
authors.forename: Sinan
authors.initials: S
authors.lastname: Liu
authors.forename: Hulin
authors.initials: H
authors.lastname: Chang
authors.forename: Ting
authors.initials: T
authors.lastname: Lin
authors.forename: Yamin
authors.initials: Y
authors.lastname: Liu
authors.forename: Wenquan
authors.initials: W
authors.lastname: Niu
authors.forename: Chang
authors.initials: C
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D004621:Embolization, Therapeutic; D005260:Female; D005838:Genotype; D005982:Glutathione Transferase / Q000096:biosynthesis / Q000235:genetics*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006801:Humans; D053208:Kaplan-Meier Estimate; D008103:Liver Cirrhosis / Q000097:blood / Q000473:pathology; D008113:Liver Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis
chemical_list: D006514:Hepatitis B Surface Antigens; C492569:GSTO2 protein, human; D005982:Glutathione Transferase
references.citation: PLoS One. 2014 Mar 04;9(3):e90862
references.pmid: 24595361
references.citation: Hepatology. 2011 Mar;53(3):1020-2
references.pmid: 21374666
references.citation: Med Oncol. 2014 Mar;31(3):843
references.pmid: 24442426
references.citation: Cancer Lett. 2005 Apr 28;221(2):135-43
references.pmid: 15808399
references.citation: Methods Enzymol. 2005;401:78-99
references.pmid: 16399380
references.citation: Sci Rep. 2014 Oct 10;4:6578
references.pmid: 25300926
references.citation: J Biol Chem. 2000 Aug 11;275(32):24798-806
references.pmid: 10783391
references.citation: Drug Metab Dispos. 2006 Jul;34(7):1237-46
references.pmid: 16638819
references.citation: Cell Biol Int. 2007 Aug;31(8):805-14
references.pmid: 17376711
references.citation: Eur J Cancer. 2012 Mar;48(5):599-641
references.pmid: 22424278
references.citation: Cancer Lett. 2006 May 18;236(2):276-81
references.pmid: 15992993
references.citation: Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11733-7
references.pmid: 7972132
references.citation: Cancer Chemother Pharmacol. 2005 Jun;55(6):511-21
references.pmid: 15761769
references.citation: Mol Oncol. 2009 Feb;3(1):67-76
references.pmid: 19383368
references.citation: Mol Biol Rep. 2011 Oct;38(7):4309-13
references.pmid: 21113667
references.citation: Br J Surg. 2003 Mar;90(3):325-31
references.pmid: 12594668
references.citation: World J Gastroenterol. 2010 Jul 7;16(25):3161-7
references.pmid: 20593501
references.citation: J Cancer Res Clin Oncol. 2009 May;135(5):673-8
references.pmid: 18941778
references.citation: Adv Cancer Res. 1979;29:175-274
references.pmid: 474272
references.citation: World J Gastroenterol. 2012 Dec 28;18(48):7242-50
references.pmid: 23326129
references.citation: J Proteome Res. 2007 Feb;6(2):772-80
references.pmid: 17269733
references.citation: Mol Biol Rep. 2009 Apr;36(4):781-4
references.pmid: 18398695
references.citation: Gastroenterology. 2006 Aug;131(2):461-9
references.pmid: 16890600
references.citation: J Exp Clin Cancer Res. 2006 Mar;25(1):107-14
references.pmid: 16761626
references.citation: Lancet. 2002 May 18;359(9319):1734-9
references.pmid: 12049862
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Mol Neurodegener. 2012 Apr 11;7:13
references.pmid: 22494505
references.citation: Eur J Radiol. 2013 Apr;82(4):577-82
references.pmid: 23246330
references.citation: Hepatology. 2002 May;35(5):1164-71
references.pmid: 11981766
references.citation: Lancet Oncol. 2004 Jul;5(7):409-18
references.pmid: 15231247
references.citation: Radiology. 2012 Jan;262(1):43-58
references.pmid: 22190656
references.citation: Hepatol Int. 2011 Dec;5(4):975-84
references.pmid: 21533669